{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:12:38Z","timestamp":1763017958499},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To discuss the heterogeneity of atherosclerotic cardiovascular disease (ASCVD) risk in heterozygous familial hypercholesterolemia and evidence and limitations of clinical risk scores and subclinical coronary atherosclerosis (SCA) imaging to evaluate risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Risk evaluation in contemporary familial hypercholesterolemia cohorts needs to consider the cause of the familial hypercholesterolemia phenotype, for example the presence of autosomal molecular defects that impart a greater ASCVD risk than in polygenic hypercholesterolemia, prospective follow-up and the impact of statin treatment. As atherosclerosis is multifactorial, clinical scores like the Montreal familial hypercholesterolemia score and SAFEHEART risk equation have been proposed to stratify ASCVD in statin-treated, molecularly defined familial hypercholesterolemia individuals. However, these scores need further validation. SCA distribution in familial hypercholesterolemia individuals undergoing conventional lipid-lowering treatment is heterogeneous, with 45\u201350% of individuals not presenting any coronary artery calcification (CAC). One study suggests that the absence of CAC associates with no ASCVD events in asymptomatic familial hypercholesterolemia individuals undergoing statin therapy despite elevated residual LDL-cholesterol levels. In contrast, the presence of CAC was independently associated with ASCVD events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>ASCVD risk is heterogeneous in statin-treated familial hypercholesterolemia individuals. Further studies are necessary to determine how risk stratification, especially with SCA detection, impacts on prescription of proprotein convertase subtilisin kexin type 9 inhibitors within a cost-constrained environment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000573","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T04:11:14Z","timestamp":1547611874000},"page":"82-87","source":"Crossref","is-referenced-by-count":10,"title":["Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment"],"prefix":"10.1097","volume":"30","author":[{"given":"Marcio H.","family":"Miname","sequence":"first","affiliation":[{"name":"Heart Institute (InCor) University of Sao Paulo Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio S.","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein"},{"name":"School of Medicine, Faculdade Israelita de Cie\u0302ncia da Sau\u0301de Albert Einstein"},{"name":"Center for Clinical and Epidemiological Research, University Hospital and Sa\u0303o Paulo State Cancer Institute, University of Sa\u0303o Paulo, Sa\u0303o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation and Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[{"name":"Heart Institute (InCor) University of Sao Paulo Medical School Hospital"},{"name":"Hospital Israelita Albert Einstein"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2018.08.021","article-title":"Familial hypercholesterolemia prevalence in an admixed racial society: sex and race matter. The ELSA-Brasil","volume":"277","author":"Harada","year":"2018","journal-title":"Atherosclerosis"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries: the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","year":"2018","journal-title":"Atherosclerosis"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2016.10.004","article-title":"The Montreal-FH-SCORE: a new score to predict cardiovascular events in familial hypercholesterolemia","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2016.05.023","article-title":"Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia","volume":"250","author":"Silva","year":"2016","journal-title":"Atherosclerosis"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","article-title":"Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab","volume":"12","author":"Ridker","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R15-20230917","article-title":"2018\u200aAHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2010.461","article-title":"Coronary artery calcium score and risk classification for coronary heart disease prediction","volume":"303","author":"Polonsky","year":"2010","journal-title":"JAMA"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"f1654","DOI":"10.1136\/bmj.f1654","article-title":"Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis","volume":"346","author":"Kramer","year":"2013","journal-title":"BMJ"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/heartjnl-2017-312706","article-title":"Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia","volume":"104","author":"Mundal","year":"2018","journal-title":"Heart"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.atherosclerosis.2017.05.015","article-title":"Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia","volume":"263","author":"Sharifi","year":"2017","journal-title":"Atherosclerosis"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jacl.2017.07.008","article-title":"Cardiovascular disease in familial hypercholesterolemia: validation and refinement of the Montreal-FH-SCORE","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2007.12.014","article-title":"No correlation and low agreement of imaging and inflammatory atherosclerosis\u2019 markers in familial hypercholesterolemia","volume":"200","author":"Martinez","year":"2008","journal-title":"Atherosclerosis"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2010.10.001","article-title":"Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia","volume":"213","author":"Miname","year":"2010","journal-title":"Atherosclerosis"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.atherosclerosis.2011.09.052","article-title":"Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia","volume":"219","author":"Neefjes","year":"2011","journal-title":"Atherosclerosis"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacl.2018.04.003","article-title":"Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study","volume":"12","author":"Perez de Isla","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.amjcard.2007.05.034","article-title":"Relation of coronary artery calcium to flow-mediated dilation and C-reactive protein levels in asymptomatic patients with heterozygous familial hypercholesterolemia","volume":"100","author":"Ye","year":"2007","journal-title":"Am J Cardiol"},{"key":"R28-20230917","article-title":"Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy","author":"Miname","year":"2018","journal-title":"JACC: Cardiovascular Imaging"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201904000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:13:30Z","timestamp":1694938410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201904000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000573","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}